Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.
Identifieur interne : 000F66 ( Ncbi/Curation ); précédent : 000F65; suivant : 000F67Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.
Auteurs : Bruno Dubois [France] ; Eduardo Tolosa ; Regina Katzenschlager ; Murat Emre ; Andrew J. Lees ; Günther Schumann ; Emmanuelle Pourcher ; Julian Gray ; Gail Thomas ; Jina Swartz ; Timothy Hsu ; Margaret L. MolineSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2012.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Analysis of Variance, Cholinesterase Inhibitors (therapeutic use), Dementia (complications), Dementia (drug therapy), Dose-Response Relationship, Drug, Double-Blind Method, Europe, Female, Humans, Indans (therapeutic use), Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy), Piperidines (therapeutic use), Psychiatric Status Rating Scales.
- MESH :
- chemical , therapeutic use : Cholinesterase Inhibitors, Indans, Piperidines.
- geographic : Europe.
- complications : Dementia, Parkinson Disease.
- drug therapy : Dementia, Parkinson Disease.
- Adult, Aged, Aged, 80 and over, Analysis of Variance, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales.
Abstract
Parkinson's disease dementia (PDD) is associated with cholinergic deficits. This report presents an efficacy and safety study of the acetylcholinesterase inhibitor donepezil hydrochloride in PDD. PDD patients (n = 550) were randomized to donepezil (5 or 10 mg) or placebo for 24 weeks. Coprimary end points were the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinician's Interview-Based Impression of Change plus caregiver input (CIBIC+; global function). Secondary end points measured executive function, attention, activities of daily living (ADLs), and behavioral symptoms. Safety and tolerability were assessed. ADAS-cog mean changes from baseline to week 24 (end point) were not significant for donepezil in the intent-to-treat population by the predefined statistical model (difference from placebo: -1.45, P = .050, for 5 mg; -1.45, P = .076, for 10 mg). Alternative ADAS-cog analysis, removing the treatment-by-country interaction term from the model, revealed significant, dose-dependent benefit with donepezil (difference from placebo: -2.08, P = .002, for 5 mg; -3.31, P < .001, for 10 mg). The 10-mg group, but not the 5-mg group, had significantly better CIBIC+ scores compared with placebo (3.7 vs 3.9, P = .113, for 5 mg; 3.6 vs 3.9, P = .040, for 10 mg). Secondary end points-Mini-Mental State Exam; Delis-Kaplan Executive Function System; Brief Test of Attention, representing cognitive functions particularly relevant to PDD-showed significant benefit for both donepezil doses (P ≤ .007). There were no significant differences in ADLs or behavior. Adverse events were more common with donepezil but mostly mild/moderate in severity. Although the study did not achieve its predefined primary end points, it presents evidence suggesting that donepezil can improve cognition, executive function, and global status in PDD. Tolerability was consistent with the known safety profile of donepezil. © 2012 Movement Disorder Society.
DOI: 10.1002/mds.25098
PubMed: 22915447
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000835
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000799
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000799
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000F66
Links to Exploration step
pubmed:22915447Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.</title>
<author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name>
<affiliation wicri:level="1"><nlm:affiliation>Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMR-S975, France. bruno.dubois@psl.aphp.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMR-S975</wicri:regionArea>
<wicri:noRegion>UMR-S975</wicri:noRegion>
<wicri:noRegion>UMR-S975</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name>
</author>
<author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name>
</author>
<author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name>
</author>
<author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J" last="Lees">Andrew J. Lees</name>
</author>
<author><name sortKey="Schumann, Gunther" sort="Schumann, Gunther" uniqKey="Schumann G" first="Günther" last="Schumann">Günther Schumann</name>
</author>
<author><name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name>
</author>
<author><name sortKey="Gray, Julian" sort="Gray, Julian" uniqKey="Gray J" first="Julian" last="Gray">Julian Gray</name>
</author>
<author><name sortKey="Thomas, Gail" sort="Thomas, Gail" uniqKey="Thomas G" first="Gail" last="Thomas">Gail Thomas</name>
</author>
<author><name sortKey="Swartz, Jina" sort="Swartz, Jina" uniqKey="Swartz J" first="Jina" last="Swartz">Jina Swartz</name>
</author>
<author><name sortKey="Hsu, Timothy" sort="Hsu, Timothy" uniqKey="Hsu T" first="Timothy" last="Hsu">Timothy Hsu</name>
</author>
<author><name sortKey="Moline, Margaret L" sort="Moline, Margaret L" uniqKey="Moline M" first="Margaret L" last="Moline">Margaret L. Moline</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22915447</idno>
<idno type="pmid">22915447</idno>
<idno type="doi">10.1002/mds.25098</idno>
<idno type="wicri:Area/PubMed/Corpus">000835</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000835</idno>
<idno type="wicri:Area/PubMed/Curation">000799</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000799</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000799</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000799</idno>
<idno type="wicri:Area/Ncbi/Merge">000F66</idno>
<idno type="wicri:Area/Ncbi/Curation">000F66</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.</title>
<author><name sortKey="Dubois, Bruno" sort="Dubois, Bruno" uniqKey="Dubois B" first="Bruno" last="Dubois">Bruno Dubois</name>
<affiliation wicri:level="1"><nlm:affiliation>Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMR-S975, France. bruno.dubois@psl.aphp.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), UMR-S975</wicri:regionArea>
<wicri:noRegion>UMR-S975</wicri:noRegion>
<wicri:noRegion>UMR-S975</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name>
</author>
<author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name>
</author>
<author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name>
</author>
<author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J" last="Lees">Andrew J. Lees</name>
</author>
<author><name sortKey="Schumann, Gunther" sort="Schumann, Gunther" uniqKey="Schumann G" first="Günther" last="Schumann">Günther Schumann</name>
</author>
<author><name sortKey="Pourcher, Emmanuelle" sort="Pourcher, Emmanuelle" uniqKey="Pourcher E" first="Emmanuelle" last="Pourcher">Emmanuelle Pourcher</name>
</author>
<author><name sortKey="Gray, Julian" sort="Gray, Julian" uniqKey="Gray J" first="Julian" last="Gray">Julian Gray</name>
</author>
<author><name sortKey="Thomas, Gail" sort="Thomas, Gail" uniqKey="Thomas G" first="Gail" last="Thomas">Gail Thomas</name>
</author>
<author><name sortKey="Swartz, Jina" sort="Swartz, Jina" uniqKey="Swartz J" first="Jina" last="Swartz">Jina Swartz</name>
</author>
<author><name sortKey="Hsu, Timothy" sort="Hsu, Timothy" uniqKey="Hsu T" first="Timothy" last="Hsu">Timothy Hsu</name>
</author>
<author><name sortKey="Moline, Margaret L" sort="Moline, Margaret L" uniqKey="Moline M" first="Margaret L" last="Moline">Margaret L. Moline</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Analysis of Variance</term>
<term>Cholinesterase Inhibitors (therapeutic use)</term>
<term>Dementia (complications)</term>
<term>Dementia (drug therapy)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Europe</term>
<term>Female</term>
<term>Humans</term>
<term>Indans (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Piperidines (therapeutic use)</term>
<term>Psychiatric Status Rating Scales</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Cholinesterase Inhibitors</term>
<term>Indans</term>
<term>Piperidines</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Europe</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Dementia</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dementia</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Analysis of Variance</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Psychiatric Status Rating Scales</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Parkinson's disease dementia (PDD) is associated with cholinergic deficits. This report presents an efficacy and safety study of the acetylcholinesterase inhibitor donepezil hydrochloride in PDD. PDD patients (n = 550) were randomized to donepezil (5 or 10 mg) or placebo for 24 weeks. Coprimary end points were the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinician's Interview-Based Impression of Change plus caregiver input (CIBIC+; global function). Secondary end points measured executive function, attention, activities of daily living (ADLs), and behavioral symptoms. Safety and tolerability were assessed. ADAS-cog mean changes from baseline to week 24 (end point) were not significant for donepezil in the intent-to-treat population by the predefined statistical model (difference from placebo: -1.45, P = .050, for 5 mg; -1.45, P = .076, for 10 mg). Alternative ADAS-cog analysis, removing the treatment-by-country interaction term from the model, revealed significant, dose-dependent benefit with donepezil (difference from placebo: -2.08, P = .002, for 5 mg; -3.31, P < .001, for 10 mg). The 10-mg group, but not the 5-mg group, had significantly better CIBIC+ scores compared with placebo (3.7 vs 3.9, P = .113, for 5 mg; 3.6 vs 3.9, P = .040, for 10 mg). Secondary end points-Mini-Mental State Exam; Delis-Kaplan Executive Function System; Brief Test of Attention, representing cognitive functions particularly relevant to PDD-showed significant benefit for both donepezil doses (P ≤ .007). There were no significant differences in ADLs or behavior. Adverse events were more common with donepezil but mostly mild/moderate in severity. Although the study did not achieve its predefined primary end points, it presents evidence suggesting that donepezil can improve cognition, executive function, and global status in PDD. Tolerability was consistent with the known safety profile of donepezil. © 2012 Movement Disorder Society.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F66 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000F66 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:22915447 |texte= Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:22915447" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |